Trinity Biotech Plc  (TRIB)
Other Ticker:  
Price: $2.1500 $-0.03 -1.376%
Day's High: $2.25 Week Perf: -6.52 %
Day's Low: $ 2.15 30 Day Perf: 264.41 %
Volume (M): 4 52 Wk High: $ 2.60
Volume (M$): $ 9 52 Wk Avg: $0.77
Open: $2.25 52 Wk Low: $0.37

 Market Capitalization (Millions $) 72
 Shares Outstanding (Millions) 34
 Employees 569
 Revenues (TTM) (Millions $) 75
 Net Income (TTM) (Millions $) -41
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 1

Trinity Biotech Plc
Trinity Biotech Plc is a leading global provider of medical diagnostic testing solutions.
The company is headquartered in Bray, Ireland, and has operations in over 100 countries.
Trinity Biotech offers a broad range of medical diagnostic products, including tests for infectious diseases, sexually transmitted infections, autoimmune disorders, and blood disorders.
The company's flagship products include the Uni-GoldTM HIV rapid test, the CaptiaTM Lyme IgG and IgM tests, and the EUROBIOLINE Autoimmune product line.
Trinity Biotech has a strong focus on research and development, with a team of scientists continually developing new diagnostic products to meet the evolving needs of the healthcare industry.
The company has a number of patents and patent applications for its diagnostic technologies.
In addition to its diagnostic products, Trinity Biotech offers a range of services to support its customers, including training, technical support, and laboratory services.
The company has a global network of distribution partners and operates manufacturing facilities in Ireland, the United States, and Italy.
Trinity Biotech has been listed on the NASDAQ stock exchange since 1992.

   Company Address: IDA Business Park Bray, County Wicklow 0
   Company Phone Number: 1276 9800   Stock Exchange / Ticker: NASDAQ TRIB
   TRIB is expected to report next financial results on May 15, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Product Service News

Trinity Biotech Plc Boosts Investor Value with Finalized Ratio Change for ADSs

Published Thu, Feb 15 2024 5:35 PM UTC

Trinity Biotech Plc Finalizes ADS Ratio Change, Offering Greater Value to InvestorsDublin, Ireland, Feb. 15, 2024 - Trinity Biotech Plc. (NASDAQ: TRIB), a leading biotechnology company, has announced the finalization of the effective date for its ratio change of its American depositary shares (ADSs). The change will now see one (1) ADS representing twenty (20) Class A ordina...


Trinity Biotech Plc. Announces Change in Ratio of ADSs; Share Price Up by 16.89% in the Past 90 Days

Published Tue, Feb 13 2024 2:01 PM UTC

Trinity Biotech Plc., a leading global developer and manufacturer of medical diagnostic products, has recently made an exciting announcement that will significantly impact its shareholders. The company disclosed its plan to change the ratio of American depositary shares (ADSs) representing its Class A ordinary shares. Currently, one ADS represents four Class A ordinary ...

Management Announcement

Trinity Biotech's Strategic Application for Early Sjogren's Syndrome Test Panel PLA Code Aims to Turn Around Financial Performance and Expand Market Reach

Published Wed, Feb 7 2024 1:30 PM UTC

Trinity Biotech Plc, a leading healthcare company, has recently announced that its New York-based reference laboratory, Immco Diagnostics, has applied for a Proprietary Laboratory Analyses (PLA) code for its Early Sjogren's Syndrome Test Panel. This strategic move aims to enhance market access and increase profitability for the company. However, it comes amidst Tri...


Trinity Biotech and Bayer Forge Partnership to Transform Diabetes Care in China and India with Innovative CGM Biosensor Device

Published Wed, Jan 31 2024 12:02 PM UTC

Trinity Biotech Announces Partnership with Bayer for Launch of CGM Biosensor Device in China and IndiaDublin, Ireland - January 31, 2024 - Trinity Biotech plc (Nasdaq: TRIB) has made an exciting revelation today as the company enters into a non-binding Letter of Intent with Bayer. This strategic partnership aims to launch a Continuous Glucose Monitoring (CGM) biosensor devic...

Merger and Acquisition

Trinity Biotech Announces Strategic Move into Expanding Biosensor Market with Acquisition of CGM Assets

Published Wed, Jan 31 2024 12:00 PM UTC

Trinity Biotech's New Strategy in the Expanding Biosensor Market
Trinity Biotech Plc, a company known for its development, manufacturing, and marketing of diagnostic products for clinical laboratories and point-of-care testing, has recently announced its repositioning strategy in the rapidly expanding biosensor market. With a new management in place, the company aims to ...


Trinity Biotech Plc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com